Skip to main content
Equibles
MNOV logo

MNOV · Medicinova Inc

Track MNOV — free

Use MNOV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MNOV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.78 +0.15 (+9.20%) At close · Oct 2
Rebalance outlook locked
Market Cap
$126.99M
Shares
49.22M
Volume · Oct 2 275.01K Avg daily vol (3M) 317.45K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.78 Open$1.67 Day$1.67–1.84 52W close$1.18–3.45 Avg vol 30d636K Short int375K · 0.8% float · 4.3d Short vol45% DataJan 2020–Oct 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$920,481
Trailing 12 months
Net income (TTM)
−$10.75M
Trailing 12 months
Revenue growth YoY
+240.6%
Year over year
Operating margin
-3,242.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.4%
Year over year · more shares
Price change (1Y)
+43.5%
Trailing year
Short interest
0.8%
Latest settlement · 4.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +18%
above
Price vs 50-day avg +3%
above
RSI (14) 43
neutral
MACD trend Negative
52-week position 26%
mid-range
Momentum
relative strength
Very Strong
1-month return +10%
trailing
6-month return +24%
trailing
YTD return +36%
this year
Relative strength +11%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +3 funds added
Insider flow Distributing
Net -$1.7M over 90 days · 100% sells
Short interest Rising
0.76% of float · ▲ +1.3% MoM · 4.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
29 holders — mid 3-yr range
Squeeze score 40
low risk · 0–100
Fundamentals
Weak
EPS growth −4%
Y/Y
Free cash flow $-9.8M
Balance sheet $13.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −53%
past year
ATR 16.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+18% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
26% Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +3 funds added
Insider flow Distributing
Net -$1.7M over 90 days · 100% sells
Short interest Rising
0.76% of float · ▲ +1.3% MoM · 4.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
29 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 26% Range high $3
vs 200-day avg +18% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MNOV
Medicinova Inc
this stock
$126.99M +35.9% — — 0.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
29
% held
10.5%
Net QoQ
-226.4K sh
Top holder
Essex Woodlands Managemen…
Held Float
View
Held by Funds
Fund positions
16
View
Short & Settlement
Short Interest Rising
Shares short
374.7K
Days to cover
4.3d
Change
+5.0K sh
View
Short Volume
Short vol %
45%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
8.2K
Value
$13.3K
As of
Sep 4, 2026
View
Off-Exchange
Off-exchange %
54.2%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.7M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$409.7K
Net income (FY)
$-12.0M
EPS diluted
$-0.24
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 28, 2026
This year
9
View

Performance

5D 20D 120D MTD YTD
MNOV -31.0% +9.9% +23.6% +6.3% +35.9%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -30.8% +10.3% +11.4% +5.4% +23.0%
Key facts CIK 1226616 CUSIP 58468P206 13F (30d) 1 filings 1 filers Visit website Investor relations